Drug profile · INN
cosibelimab-ipdl
UNLOXCYT
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
cosibelimab-ipdl (UNLOXCYT) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN cosibelimab-ipdl
Brand UNLOXCYT
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is cosibelimab-ipdl?
cosibelimab-ipdl (UNLOXCYT) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for cosibelimab-ipdl?
UNLOXCYT is a marketed brand name for cosibelimab-ipdl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cosibelimab-ipdl?
cosibelimab-ipdl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.